Drug Profile
Olopatadine extended release - Sun Pharmaceutical Industries
Alternative Names: Olopatadine controlled release - Sun Pharmaceutical Industries; Olopatadine OD - Sun Pharmaceutical IndustriesLatest Information Update: 22 Feb 2016
Price :
$50
*
At a glance
- Originator Ranbaxy Laboratories
- Developer Sun Pharmaceutical Industries
- Class Antiallergics; Antihistamines; Dibenzoxepins; Small molecules
- Mechanism of Action Histamine H1 receptor antagonists; Leukotriene B4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Seasonal allergic rhinitis
Most Recent Events
- 22 Feb 2016 Discontinued - Phase-III for Seasonal allergic rhinitis in India (PO)
- 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
- 20 Sep 2011 Ranbaxy Laboratories completes a phase III trial in Seasonal allergic rhinitis in India (CTRI/2010/091/001058)